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Abstract
Purpose of Review Syringe access programs (SAPs) are cornerstone harm reduction interventions for combatting the national 
opioid epidemic. The goal of this paper is to describe effective advocacy strategies for enacting syringe decriminalization 
legislation to foster the expansion of SAPs in high-need areas amidst political opposition.
Recent Findings Decades or research shows that SAPs prevent the transmission of HIVamong people who inject drugs (PWID) 
and are a cost-effective tool for linking PWID to medical care, health education, and social services. In the USA, state laws 
criminalizing distribution and possession of syringes impede the expansion of SAPs into areas where they are sorely needed. 
Summary In 2016, North Carolina became the first state to legalize SAPs with a Republican super majority. This paper distills 
strategies for community organizations seeking to advance syringe decriminalization legislation in politically conservative states 
with histories of prioritizing punitive sanctions over public health responses to drug use.
Keywords HIV . Harm reduction . North Carolina . Syringe access programs
Introduction
HIV, Hepatitis C, and Overdoses in North Carolina
The opioid epidemic is taking a grave toll on the health and
longevity of communities across North Carolina. While rates
have declined, HIV/AIDS is still an entrenched problem in
North Carolina. The Tar Heel state ranks eighth in total num-
ber of new HIV/AIDS diagnoses in the country, which is four
times the national average [1]. Statewide, between 2010 and
2014, reported cases of Hepatitis C (HCV) tripled with young
adults (ages 20–39 years) comprising the largest share
(67.6%) of newly reported diagnoses. However, true HCV
burden is certainly larger since an estimated 50% of people
infected with the virus are unaware or undiagnosed [2]. People
living in counties along North Carolina’s western corner and
eastern coast are most heavily burdened by HCV [3]. State
officials estimate that the annual cost of treating HCVamong
Medicaid beneficiaries ballooned from 8 to 50 million dollars
from 2013 to 2015 [4].
Sharing syringes, cookers, water, and other injection
equipment is a leading risk factor for transmission of
HIV and other blood-borne diseases [5]. Among North
Carolinians, an estimated 9.4% of diagnosed HIV cases
among men and 19.3% among women were acquired
through IDU, respectively [6]. In 2014, the state’s
Division of Public Health reported that 84% of new acute
HCV diagnoses were acquired via injection drug use (IDU)
[3]. Opioid-related overdose deaths are also on the rise.
Between 2010 and 2015, for example, heroin-related, fatal
overdoses increased by 884%, from 0.47 per 1000 deaths
to 4.08 per 1000 deaths in North Carolina [6]. People who
inject drugs (PWID) experience excess risk of overdose
compared to people snorting, smoking, or ingesting opi-
oids [7]. PWID also experience disparately high rates of
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untreated, chronic health problems, and bacterial infections
that require care [8, 9]. For example, in North Carolina,
reported cases of endocarditis, a bacterial heart valve in-
fection associated with injection drug use, increased more
than 13-fold from 2009 to 2014 [3, 10, 11].
Syringe Access Programs
Syringe access programs (SAPs) are a cornerstone harm
reduction intervention. Decades of scientific research
demonstrate their effectiveness in curbing the spread of
blood-borne diseases among people who inject drugs
(PWID) by distributing sterile syringes and disposing of
used ones [12–17]. Importantly, SAPs also provide ben-
efits beyond communicable disease prevention. Most
programs directly deliver or facilitate linkages to an array
of health and social services, including drug treatment,
overdose prevention, health education, chronic disease
management, wound care, and assistance obtaining
health insurance, housing, food, and social entitlements.
Increasingly, SAPs train and supply PWID with kits for
administering naloxone, a highly effective antidote for
reversing respiratory failure from opioid overdose [18].
Studies have shown that SAP participants are significant-
ly more likely to seek drug treatment than those not
using the program [19, 20]. Finally, empirical evidence
has confirmed that SAPs do not increase levels of drug
use or breed crime, a common misconception of policy
opponents [21, 22].
The Centers for Disease Control and Prevention (CDC),
American Public Health Association, American Society on
Addiction Medicine, National Association of County and
City Health Officials, amongmany other US health authorities
have urged state and local governments to create and expand
SAPs as an essential strategy for addressing HIV, HCV, and
other harms associated with IDU [23–26]. Yet, according to
surveys conducted by the North American Syringe Exchange
Network, there are only 264 SAPs operating nationwide [27].
These vital programs are non-existent or insufficiently scaled
to reach people who would benefit from their services, espe-
cially those living outside urban centers. In 2015, the CDC
found that 69% of SAPs are located in cities, compared to only
20 and 9% in rural and suburban areas, respectively. They also
found that only 37% of programs in rural areas offer naloxone
kits, compared with 61% of urban programs [28]. During a
2016 public briefing speaking to the results of this survey,
former CDC director, Dr. Tom Frieden, called for expanded
SAP coverage nationwide.
“[SAPs] help prevent thousands of cases of HIV and
save literally hundreds of millions of dollars.
However…there is still a large unmet need for sterile
injection equipment. This finding reinforces the concern
that outbreaks could occur in people who inject drugs in
areas where sources of sterile equipment are limited.”
Legal Barriers to SAPs and Harm Reduction
Since the late 1980s, political opposition to harm reduction
has hindered the adoption of laws necessary for establishing
SAPs in high-need areas. Broadly, policymakers’ resistance to
SAPs is rooted in an array of interrelated factors: moralistic
condemnation of addiction and psychoactive substances,
dominance of abstinence-only-based philosophies within
mainstream treatment systems, misconceptions about risks
of increased drug use and crime, and forces of structural rac-
ism giving rise to the US war on drugs and mass incarceration
[29–32]. In prior decades, as the HIVepidemic began spread-
ing among networks of PWID and Black communities in ma-
jor cities, support for SAPs among lawmakers was sorely
lacking [29]. Since, except for a brief period between 2009
and 2011, federal law prohibited federal funding for SAPs.
While the AIDS epidemic was intensifying, the US
Department of Health and Human Services (HHS) denied
finances to support SAPs on the grounds that there was no
conclusive evidence demonstrating their effectiveness and
safety. Yet, in the same breath, federal officials also prohibited
the use of federal dollars to support SAP research, which sig-
nificantly hampered the progress of activists and scientists
committed to piloting and testing the effects of SAPs [30].
Opposition to SAPs has waned at the federal level in recent
years. A shift in the demographic and geographic burden of
drug-related harms from urban communities of color into rural
and suburban epicenters of white America is prompting gov-
ernment responses that are comparatively more compassion-
ate and treatment-oriented than the wave of policing and in-
carceration waged on Black communities in prior decades. In
2016, with Republican leadership, Congress effectively lifted
the federal ban on SAPs by authorizing states and local gov-
ernments to use federal grants for more costly aspects of op-
erating a program, such as rent, gas, and staffing, while still
forbidding purchase of sterile injection equipment [33].
Shortly thereafter, HHS and the CDC issued guidance for
states and local agencies to request federal support for SAPs
in their jurisdiction [34].
However, state laws criminalizing possession of syrin-
ges and enforcement tactics prioritizing arrest, prosecution,
and incarceration in response to drug-use behaviors are
structural barriers that preventing health departments and
harm reduction organizations from capitalizing on changes
in federal policy to establish SAPs in high-needs areas. As
of 2017, SAPs remain illegal in 29 states, all of which have
Republican-controlled legislatures [35]. Southern states
with longstanding disparities in HIV, viral hepatitis, and
other blood-borne diseases are among the slowest to pur-
sue SAP legislation [35–39]. Importantly, four additional
states with Republican super majorities, Florida, North
Dakota, Tennessee, and Utah passed bills authorizing the
operation of SAPs. Yet, other proposals have continuously
failed to gain traction in other states with disproportionate-
ly high rates of HIV, including Georgia, Alabama,
Mississippi, South Carolina, and Texas. Without legislative
action, communities that have long-endured HIV dispar-
ities and those on the cusp of unprecedented HIV and
HCV outbreaks are imperiled.
Harm Reduction Advocacy in Red States
On July 11, 2016, North Carolina became the first state to pass
a bill authorizing the operation of SAPs with a Republican
super majority [40]. The North Carolina Harm Reduction
(NCHRC), a small non-profit organization led by co-authors
Castillo and Childs, orchestrated a novel advocacy campaign
that resulted in this improbable victory. The law includes pro-
visions designed for operating SAPs across urban, suburban,
and rural terrains. One provision allows harm reduction orga-
nizations, AIDS Service Organizations, Faith Centers,
community-based organizations, and health departments to
start a “needle and hypodermic syringe exchange program”
[40]. The law does not require organizations to acquire state or
local approval before starting a SAP. Rather, programs are
only required to notify state health officials and coordinate
with local law enforcement agencies [40]. This flexibility
has empowered coalitions of advocates and health service
providers to promptly establish programs where they are most
needed. In contrast, other states, such as Kentucky, only per-
mit local health departments to operate SAPs after receiving
local health board approval [41]. However, such rules risk
crowding out organizations with the closest relationships,
established trust, and deepest expertise delivering health ser-
vices to PWID, sex workers, and other marginalized groups.
Permitting diverse organizations to establish programs
allowed NCHRC and other non-profits to mobilize coalitions
of advocates and service providers that were equipped to start
programs shortly after the law enacted.
Any entity starting a program is expected to deliver an
array of services, as described in the law. These include the
following: disposal of used syringes, distribution of free, ster-
ile injection equipment, educational materials on overdose,
HIV, and HCV prevention; access to naloxone kits; and per-
sonal consultations and treatment referrals for substance use
and psychiatric conditions [40]. Specifying the types of ser-
vices that SAPS are expected to provide has helped ensure that
organizations starting programs engage in careful planning
processes to ensure programs promote a holistic approach to
service delivery.
SAPs only work when participants feel empowered to
access services without fear of reprisal. Indeed, research
and experience show that people are less likely to utilize
SAP services and more likely to engage in riskier injec-
tion behaviors when they fear police and incarceration
[42–44]. Therefore, immunity from arrest and prosecution
for behaviors related to drug use is essential. North
Carolina’s law gives SAP participants, volunteers, and
staff immunity from criminal sanctions for possession of
injection supplies and residual amounts of drugs.
However, the law does require people stopped by police
to show officers an identification card to verify participa-
tion in a SAP to avoid arrest and does not imposed civil
liability on officers who arrest a SAP participant [40].
Another key provision authorizes programs to distribute
quantities of syringes and injection equipment based on a
participant’s level of need and not the number of used
syringes returned for disposal [40]. Research shows, more
restrictive, one-for-one policies are less effective in reduc-
ing HIV transmission than needs-based policies by increas-
ing the chances that people share or reuse equipment
[45–47]. Thus, NCHRC drafted language explicitly stating
that syringes and other injection supplies would be free and
distributed in quantities sufficient to ensure that injection
equipment is not shared or reused.
While convincing fiscally conservative, elected offi-
cials to budget tax dollars for providing PWID free syrin-
ges is politically difficult, advocates and public health
leaders should strive to include statutory provisions that
allow harm reduction organizations and health depart-
ments to utilize state and local funding for service deliv-
ery is important for scaling and sustaining programs.
NCHRC has made incremental, but significant progress
in acquiring public funding for SAPs. In 2015, NCHRC
reluctantly conceded to inserting a provision into the sy-
ringe decriminalization bill that precluded use of all pub-
lic funding for SAPs. Lawmakers would only bring the
bill to the floor for a vote with a promise that the govern-
ment would not bear the cost. Yet, after a couple years of
demonstrated success in operating SAP across the state,
NCHRC was able to successfully amend the syringe bill
to permit city and local governments to financially sup-
port for SAPs, which empowers local health departments,
city councils, and counties to spend their own revenue to
start/support programs [48].
Collecting data is critical for monitoring SAP implementa-
tion, assessing impact, and converting opponents to sup-
porters with evidence of impact. North Carolina’s law in-
cludes a provision delegating responsibility of monitoring im-
plementation and collecting data on service utilization to the
Division of Public Health [40]. Nearly 18 months since
Governor McCrory signed the syringe decriminalization bill
into law, 16 different organizations have started 23 different
SAPs, serving a total of 31counties across North Carolina.
While additional studies are needed, program records suggest
that SAPs and decriminalization are making a difference in
North Carolina. Altogether, these programs have distributed a
total of 1,024,226 sterile syringes to 3230 participants and
collected and disposed of more than 431,985 used syringes.
North Carolina’s SAPs have also trained more than 2600 peo-
ple of overdose prevention and handed out more than 5401
naloxone kits, made 3581 referrals into treatment.
Replicable Advocacy Tactics
Harm reduction activism that depends solely on Democratic
leadership as a vehicle for drug policy reform too often falls
short of achieving legislative change in deep red states. In
North Carolina, prior attempts to legislate increased access
to sterile syringes for PWID failed six times in North
Carolina between 1997 and 2013. In 2011, NCHRC took its
first shot at syringe decriminalization by drafting a bill and
finding support in a progressive democratic sponsor. Despite a
valiant effort to bolster voter support and educate lawmakers,
the bill flopped for two main reasons: the 2010 midterm elec-
tions had just ushered a Republican super majority into con-
trol, and two closely aligned, powerful, and conservative lean-
ing lobbying groups, the North Carolina Sheriff’s Association
and North Carolina Association of Chiefs of Police, adamant-
ly opposed syringe decriminalization out of the gates. From
this experience, NCHRC realized that maneuvering drug pol-
icy proposals thorough its legislature would require a
Republican sponsor and vocal support from law enforcement
leaders. Reflecting on NCHRC’s advocacy campaign, we of-
fer guidance to activists and public health leaders fighting to
pass legislation conducive to starting and expanding SAPs in
conservative political environments.
Community Organizing and Coalition Building
Effective advocacy campaigns start with grassroots organiz-
ing and coalition building guided by the voices of people who
use drugs and other marginalized groups. NCHRC started its
syringe decriminalization efforts by bringing together key
stakeholder groups, including people who use drugs, sex
workers, veterans, migrant workers, and people of transgender
experience to plan and implement community outreach and
advocacy strategies. As part of strategy, NCHRC organized an
HIV/Syringe Decriminalization advocacy day, a Sex Work
Summit, and the first Southern Harm Reduction Conference.
As NCHRC’s coalition of supporters grows, maintaining a
comprehensive list serve of individuals, organizations,
policymakers, business leaders, and other community stake-
holders who support NCHRC’s policy goals of overdose pre-
vention, syringe decriminalization, and criminal justice reform
has proved critical. NCHRC relies on this list serve for dis-
seminating petitions, raising funds, planning community
events, educating members on reforms and where to access
direct service, and mobilizing voters during legislative ses-
sions. In 2016, NCHRC depended on the list serve to send
an emergency alert that mobilized thousands of coalition
members who made calls and sent emails to the lawmaker
who was contemplating reversing a prior commitment to in-
troduce the syringe decriminalization bill. Without this flurry
of phone calls from his constituents, this bill may not have
advanced any further that year.
Garnering Law Enforcement Support
Historically, harm reduction advocates have historically con-
sidered law enforcement entities as foes and not allies in ad-
vocating for decriminalization of drug use behaviors. Indeed,
studies show that fear of police and aggressive policing crack-
downs increase risky behaviors associated with transmission
of blood-borne diseases among PWID. However, NCHRC
developed strategies to overcome historical challenges and
pass harm reduction legislation by building new relationships
with law enforcement. As explained below, the effectiveness
of these strategies is reflected in text conveying the legislative
intent of the bill, which outlines three goals: reducing the
spread of HIV, AIDS, viral hepatitis, and other blood-borne
diseases; decreasing needle stick injuries to law enforcement
officers and other emergency personnel, and encouraging in-
dividuals who inject drugs to enroll in evidence-based treat-
ment [40].
Needle Sticks and Occupational Health
In 2012, as a first step, NCHRC decided to travel around the
state and educate police officers about HIV, HCV, and needle
stick prevention. An estimated one in three police officers get
stuck with a syringe during a body search during their careers.
Prior studies show that police officers develop increasingly
favorable attitudes toward SAPs and syringe decriminaliza-
tion, after receiving educational trainings communicating
how syringe decriminalization reduces officers’ personal risk
of needle sticks, and SAPs effectiveness in getting people into
treatment without arrest [49]. NCHRC hired a Law
Enforcement Safety Advocate to schedule and coordinate nee-
dle stick prevention training sessions with police departments
across the state. They started by reaching out to departments
that provide training for crisis intervention teams (CITs),
which are collaborative teams of officers trained to prevent
violence, avoid arrests, and facilitate appropriate linkages to
psychiatric services when responding to calls involving a per-
son in psychosis or emotional distress [51]. CIT trainings were
a natural forum to build support for SAPs. While the training
sessions were primarily about needle stick prevention,
NCHRC educated attendees on the benefits of SAPs and de-
criminalization. In doing so, they intentionally used the term
syringe access (not “exchange”) program to emphasize that
SAPs do more than swap dirty syringes for clean ones.
Linkages to Treatment and Medical Services
Prior to NCHRC trainings, most police officers did not
know that SAPs are also highly effective in getting people
into treatment among providing other benefits. Police offi-
cers expressed their own frustrations with continuously
arresting people for drug-related crimes and became more
supportive of SAPs after learning that they do more than
exchange injection equipment. In fact, an analysis of sur-
veys administered to 350 CIT officers in North Carolina
found that 60% of officers said that syringe decriminaliza-
tion would benefit the community and law enforcement
officers, after participating NCHRC trainings [49]. These
trainings helped NCHRC achieve its first small step toward
syringe decriminalization. In 2013, NCHRC compromised
to pass a law giving people immunity from criminal
charges if disclosing possession of a syringe prior to a
body search. Two years later, trying again for full syringe
decriminalization, the legislature and police lobbyist
agreed to authorize harm reduction organizations to collect
used syringes [40].
Recruiting a Republican Bill Sponsor Demonstrating support
from a key constituency is critical to gaining legislative sup-
port and sponsorship. In the case of the SAP bill, NCHRC
used surveys from law enforcement that demonstrated support
for SAPs in order to convince a Republican legislator, a for-
mer Chief of Police, to sponsor a bill. This lawmaker had
previously sponsored a Good Samaritan bill extending crimi-
nal immunity to anyone calling 911 in response to overdose.
To gain support of other key legislators, NCHRC invited them
to meetings in their districts hosted by influential members of
their community, such as public health directors, faith leaders,
and sheriffs. NCHRC collected and disseminated quotes from
law enforcement leaders across the state in support of harm
reduction and syringe decriminalization. These quotes proved
to be a powerful advocacy tool for garnering support from
lawmakers and other police departments.
Data Collection and Academic Partnerships Collaborations
between activists and academic researchers play an important
role in driving policy change in North Carolina. For example,
since law enforcement agencies started carrying and adminis-
tering naloxone, NCHRC has tracked total lives saved through
overdose reversals. Presenting data on lives being saved via
police officer naloxone administrations to lawmakers has been
invaluable for building political support for syringe decrimi-
nalization and other harm reduction measures. Additionally, in
partnership with Duke University’s nursing school, NCHRC
surveyed local pharmacies and found that 64% of owners
were willing to sell syringes to people who inject drugs, but
less than 20% were willing to have their stores serve as a
biohazard collection site for used syringes.
Conclusion
Harm reduction activists have a longer history of clashing
than collaborating with conservative lawmakers and po-
lice departments. Given this historical context and
existing power dynamics, working toward drug policy re-
form through unconventional partnerships with law en-
forcement will inevitably pose complicated ethical di-
lemmas for harm reduction activists. There are situations
in which the goals of law enforcement and harm reduc-
tionists clearly do not align. In these situations, NCHRC’s
rule of thumb is “first, do no harm.” We partnered with
law enforcement only on goals where we could both agree
on the result and made sure than any compromises made
did not cause more harm, even if there was a benefit in
another area. In time, the areas in which we agreed grew
in North Carolina, mostly due to law enforcement becom-
ing increasingly comfortable with harm reduction as a
philosophy. Advocates and lawmakers committed to drug
policy reform should focus attention on reducing stigma
and increasing access to treatment and medical insurance,
instead of overemphasizing any one particular drug used,
such as devising solutions to the opioid issues alone,
which mostly affect white consumers. SAPs are an essen-
tial tool for addressing today's opiate epidemic.
Criminalization and fear of police are formidable barriers
to creating and operating effective SAPs, even in cities
where they are legalized. Yet, the bottom line is that
SAPs cannot achieve their goals without some level of
buy-in from law enforcement. In North Carolina, and oth-
er politically conservative jurisdictions, law enforcement
agencies exert significant influence over legislative prior-
ities, especially in the area of drug use. Educating police
leaders on the occupational health benefits of SAPs for
officers and effectiveness in connecting PWID to treat-
ment is a promising strategy for building the necessary
political support for syringe decriminalization and a step
toward harm-reduction-oriented policy. Across the coun-
try, a growing number of local criminal justice systems
are looking for solutions beyond arrest and incarceration
to problems rooted in drug use, poverty, and homeless-
ness. Bridging political divides by engaging police leaders
as advocates for sounder drug policy is complicated and
imperfect, but timely and necessary for driving structural
change in the Deep South.
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